Teicoplanin
Also known as: MDL 62873, Targocid, TEIC, Teichomycin A2, Teicoplanin, Teicoplanin A2
Source Teicoplanin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Teicoplanin is a prescription glycopeptide antibiotic administered intravenously or intramuscularly for serious Gram‑positive infections, including those caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant enterococci (VRE). Clinical literature highlights its use via subcutaneous infusion as an alternative to intravenous therapy, especially when venous access is limited, and notes its role in therapeutic drug monitoring for optimal dosing.
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing transglycosylation and transpeptidation, leading to bacterial cell death
What the Research Shows
Recent reviews describe subcutaneous delivery of teicoplanin achieving pharmacokinetic/pharmacodynamic targets comparable to intravenous infusion, with stable concentrations and reduced catheter‑related complications. Studies on continuous renal replacement therapy note the need for dose adjustment, though specific recommendations remain limited. Therapeutic drug monitoring is emphasized for VRE bloodstream infections, where teicoplanin shows a defined therapeutic range and toxicity monitoring. A systematic review comparing linezolid with teicoplanin in MRSA bacteremia found similar efficacy and safety outcomes. Overall, evidence supports teicoplanin’s efficacy, tolerability, and flexibility of administration routes, while highlighting gaps in dosing guidance for renal replacement modalities and resistance prevention.
Reported Benefits
Evidence indicates that teicoplanin provides efficacy comparable to other agents for MRSA and VRE infections, with good tolerability in both intravenous and subcutaneous routes. Subcutaneous infusion offers comparable PK/PD exposure to IV dosing, reducing the need for central lines and associated infections. Therapeutic drug monitoring helps maintain effective concentrations while minimizing toxicity.
Limitations of the Evidence
Data on optimal dosing during continuous renal replacement therapy are sparse, and regulatory guidance for subcutaneous use is limited. The relationship between drug exposure and resistance development remains unclear, and more clinical trials are needed to confirm subcutaneous efficacy across infection types. Guidance on dose adjustments for severe renal impairment is not well established.
Safety Considerations
Clinical experience reports good overall tolerability, with few severe adverse events. Local reactions at subcutaneous sites are generally mild, and no cases of bacteraemia related to the route have been described. Monitoring for nephrotoxicity and ototoxicity is advised, and therapeutic drug monitoring is recommended to avoid supratherapeutic levels.
How It Is Administered
Teicoplanin is approved for intravenous and intramuscular injection. Subcutaneous infusion has been described in clinical practice and research settings, typically using the standard injectable formulation diluted for slow infusion. Dosing regimens vary by infection severity and renal function, and therapeutic drug monitoring may be employed to guide adjustments.
Routes of Administration
Goals & Uses
- treatment of serious Gram‑positive infectionsAntibacterialHigh
- Treatment of skin and soft tissue infectionsAntimicrobial TherapyHigh
- Treatment of MRSA infectionsAntimicrobialHigh
- Treatment of Clostridioides difficile infectionAntimicrobialModerate
- Treatment of endocarditisAntimicrobial TherapyHigh
- Surgical prophylaxisInfection PreventionModerate
Contraindications
- Hypersensitivity to teicoplaninAllergyHigh
- Severe renal impairment (without dose adjustment)Organ ImpairmentModerate
- Known cross-reactivity with vancomycin in severe reactionsAllergyHigh
- pregnancy (first trimester)ReproductiveModerate
- hypersensitivity to teicoplanin or other glycopeptidesAllergyHigh
Adverse Effects
- rash / pruritusDermatologicCommon
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- OtotoxicityAuditory/vestibularUncommon
- Infusion‑related reactionsGeneralCommon
- Red man syndromeInfusion ReactionUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- NephrotoxicityRenalCommon
Drug Interactions
- AminoglycosidesHigh
- CiclosporinModerate
- Aminoglycosides (e.g., gentamicin)Moderate
- NSAIDsModerateMay increase renal risk in susceptible patients
- Loop diuretics (e.g., furosemide)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Neonates and infantsPediatricRelative
- Renal impairmentOrgan ImpairmentRelative
- ElderlyAgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionApprovedApproved: complicated skin and soft‑tissue infections, bacteremia, endocarditis, osteomyelitisApproved for systemic treatment of Gram‑positive infections
- United StatesUnapprovedNot approved by FDA; may be obtained via IND for investigational use
- United KingdomApprovedApproved: serious Gram‑positive infections including MRSAAvailable under prescription in NHS formulary
Not FDA‑approved in the United States; approved in the EU and many other jurisdictions for systemic infections.
Evidence & Sources
- Journal ArticleModerateDi Bella S, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateLi L, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateCairns KA, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateAbdul-Aziz MH, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateKawasuji H, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateJumpertz M, et al.2022-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of infections are treated with teicoplanin?
Teicoplanin is used for serious Gram‑positive infections, notably those caused by MRSA, coagulase‑negative staphylococci, and vancomycin‑resistant enterococci, especially when intravenous therapy is required.
Can teicoplanin be given subcutaneously?
Yes, studies report subcutaneous infusion achieving drug levels comparable to intravenous dosing, offering an alternative for patients with poor venous access or in outpatient settings.
Is therapeutic drug monitoring needed for teicoplanin?
Therapeutic drug monitoring is recommended, particularly for VRE bloodstream infections and in patients with renal replacement therapy, to ensure therapeutic concentrations and avoid toxicity.
What are the main safety concerns with teicoplanin?
Teicoplanin is generally well tolerated; serious adverse events are rare. Monitoring focuses on renal function, potential ototoxicity, and local injection site reactions, especially with subcutaneous administration.
How does renal replacement therapy affect teicoplanin dosing?
Current literature indicates dosing adjustments may be required during continuous renal replacement therapy, but specific guidelines are limited, underscoring the need for individualized dosing and possible drug level monitoring.
What is Teicoplanin?
Teicoplanin is a prescription glycopeptide antibiotic administered intravenously or intramuscularly for serious Gram‑positive infections, including those caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant enterococci (VRE). Clinical literature highlights its use via subcutaneous infusion as an alternative to intravenous therapy, especially when venous access is limited, and notes its role in therapeutic drug monitoring for optimal dosing.
What is Teicoplanin used for?
Teicoplanin is educationally associated with: treatment of serious Gram‑positive infections, Treatment of skin and soft tissue infections, Treatment of MRSA infections, Treatment of Clostridioides difficile infection, Treatment of endocarditis, Surgical prophylaxis. Educational only — not medical advice.
How is Teicoplanin administered?
Recorded routes of administration: Intramuscular, Intravenous.
What are the potential side effects of Teicoplanin?
Reported adverse effects include: rash / pruritus, Injection site reactions, Thrombocytopenia, Ototoxicity, Infusion‑related reactions, Red man syndrome, Elevated liver enzymes, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Teicoplanin?
Recorded contraindications: Hypersensitivity to teicoplanin, Severe renal impairment (without dose adjustment), Known cross-reactivity with vancomycin in severe reactions, pregnancy (first trimester), hypersensitivity to teicoplanin or other glycopeptides. Consult a qualified clinician before use.